Mereo BioPharma Group Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BST:MAH0 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
13 Sep 24	Sell€109,755	Christine Fox	Individual	28,286	€4.03
13 Sep 24	Sell€119,998	Charles Sermon	Individual	30,926	€4.03
13 Sep 24	Sell€62,661	John Lewicki	Individual	16,149	€4.03
13 Sep 24	Sell€344,005	Denise Scots-Knight	Individual	88,657	€4.03
13 Sep 24	Sell€574,693	Alexandra Hughes-Wilson	Individual	148,110	€4.03
26 Jun 24	Sell€108,020	Alexandra Hughes-Wilson	Individual	33,102	€3.46
26 Jun 24	Sell€433,963	Denise Scots-Knight	Individual	132,985	€3.46
26 Jun 24	Sell€138,456	Christine Fox	Individual	42,429	€3.46
26 Jun 24	Sell€79,049	John Lewicki	Individual	24,224	€3.46
26 Jun 24	Sell€151,379	Charles Sermon	Individual	46,389	€3.46

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of MAH0?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	5,066,471	3.27%
General Public	33,004,120	21.3%
Hedge Funds	49,676,250	32.1%
Institutions	67,151,311	43.4%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.6%.

Top Shareholders

Top 25 shareholders own 74.49% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
14%	Rubric Capital Management LP	21,697,347	€69.7m	0%	1.29%
10.3%	Janus Henderson Group plc	15,917,259	€51.1m	28.9%	0.02%
6.27%	Adage Capital Management, L.P.	9,715,013	€31.2m	-17.6%	0.06%
6.16%	Rock Springs Capital Management LP	9,534,170	€30.6m	2.7%	1.09%
5.64%	Mangrove Partners IM, LLC	8,729,720	€28.0m	-0.26%	2.92%
4.33%	Deerfield Management Company, L.P. Series C	6,710,429	€21.5m	0%	0.4%
3.48%	Millennium Management LLC	5,394,691	€17.3m	68.5%	0.01%
3.29%	Frazier Life Sciences Management, LP	5,097,779	€16.4m	15.8%	0.66%
3.13%	683 Capital Management, LLC	4,849,800	€15.6m	-3%	1.68%
3.03%	Alkeon Capital Management, LLC	4,698,100	€15.1m	0%	0.11%
2.09%	Clearline Capital LP	3,244,334	€10.4m	-2.48%	0.95%
1.9%	Denise Scots-Knight	2,942,410	€9.4m	3.5%	no data
1.83%	Tejara Capital Limited., Asset Management Arm	2,829,990	€9.1m	8.2%	4.65%
1.52%	Morgan Stanley, Investment Banking and Brokerage Investments	2,347,825	€7.5m	1,030%	no data
1.3%	Goldman Sachs Group, Investment Banking and Securities Investments	2,008,381	€6.4m	-19.9%	no data
0.84%	Renaissance Technologies LLC	1,305,371	€4.2m	-25.9%	0.01%
0.81%	Acuta Capital Partners, LLC	1,260,700	€4.0m	86.2%	3.78%
0.66%	Marshall Wace LLP	1,028,512	€3.3m	-10.1%	no data
0.65%	Integral Health Asset Management, LLC	1,000,000	€3.2m	-43.7%	0.44%
0.58%	Charles Sermon	893,041	€2.9m	4.04%	no data
0.55%	CHI Advisors LLC	847,809	€2.7m	-5.57%	1.29%
0.55%	Soleus Capital Management, L.P.	846,953	€2.7m	-32.1%	0.22%
0.54%	Tema Global Limited, Asset Management Arm	837,909	€2.7m	16%	1.65%
0.54%	Nationwide Fund Advisors	835,194	€2.7m	-13%	0.02%
0.53%	Perceptive Advisors LLC	815,722	€2.6m	-34.9%	0.06%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 06:31
End of Day Share Price	2024/12/09 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mereo BioPharma Group plc is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jack Allen	Baird
Yun Zhong	BTIG
Julian Harrison	BTIG